Discover SCORED
INPEFA™ reduced the risk of the composite of CV death, hospitalization for HF, and urgent HF visit in patients with T2DM, CKD, and additional CV risk factors1
SCORED—a multi-center, randomized, double-blind, placebo‑controlled, Phase 3 study in 10,584 patients with type 2 diabetes mellitus, chronic kidney disease, and additional cardiovascular risk factors, evaluating the CV efficacy of INPEFA™ versus placebo when added to standard of care.1
25%risk reduction*
In the primary composite endpoint of
CV death, hospitalization for heart failure, and urgent HF visit1
HR 0.75 (95% CI: 0.63, 0.88) p<0.001
CKD=chronic kidney disease; CV=cardiovascular;HF=heart failure;T2DM=type 2 diabetes mellitus.
*Relative risk reduction.
25% risk reduction* in the primary composite endpoint of CV death, hospitalization for HF, and urgent HF visit1
In a cumulative events plot of the primary endpoint, the INPEFA™ and placebo event curves separated early and continued to diverge over the study period following randomization.
Primary Endpoint

CI=confidence interval; HR=hazard ratio.
*Relative risk reduction.
INPEFA™ SCORED study adverse events
Adverse reactions reported in ≥2% of patients treated with INPEFA